Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOSE-2: PFO Closure vs Anticoagulants vs Antiplatelets in Older Patients with PFO-associated Stroke
NCT05387954Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2023
- Primary completion
- Jul 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in cryptogenic ischemic stroke and patent foramen ovale (PFO) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Time to recurrent stroke (ischemic or hemorrhagic fatal or non-fatal) up to 8 years. Started Jul 2023; status: recruiting.
02
Conditions
cryptogenic ischemic strokepatent foramen ovale (PFO)
Beyond the preview
Go deeper on NCT05387954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387954.